IRVINE, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today they have submitted to the FDA an EUA application for an ELISA lab-based serology blood test for the ...
Avacta Group plc, the developer of Affimer ® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global ...
CAMBRIDGE & WETHERBY, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory ...
Drug developer Avacta expects to launch a new laboratory test for the SARS-CoV-2 spike protein in the next few weeks. Did you know with a Digital subscription to Yorkshire Post, you can get access to ...
The ELISA Test Market's growth is driven by rising infectious and chronic diseases, enhancing demand for accurate diagnostics. Opportunities lie in technological advancements, like point-of-care ...
A desire for a simpler, cheaper way to do common laboratory tests for medical diagnoses and to avoid "washing the dishes" led University of Connecticut researchers to develop a new technology that ...
A desire for a simpler, cheaper way to do common laboratory tests for medical diagnoses and to avoid 'washing the dishes' led researchers to develop a new technology that reduces cost and time. The 3D ...
IRVINE, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today they have submitted to the FDA an EUA application for an ELISA lab-based serology blood test for the ...
Avacta to make a high performance Affimer research ELISA test available to support global research efforts to combat the coronavirus Avacta Group plc (AIM: AVCT), the developer of Affimer® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback